In the present study, we performed a cause-of-death analysis among the subjects of the RE-LY trial and used competing-risk methodology to identify independent predictors for cardiac death (sudden cardiac death [SCD] and progressive heart failure), as well as stroke-and hemorrhage-related deaths.
Methods

Trial Design
RE-LY was a randomized trial designed to compare 2 fixed doses of dabigatran etexilate, a direct thrombin inhibitor, each administered in a blinded manner, with open-label use of warfarin in patients who had AF and were at increased risk for stroke. The design of this study has been described previously. 9, 10 The study was approved by all appropriate national regulatory authorities and ethics committees of the participating centers. All patients provided written informed consent. Briefly, patients were recruited from 951 clinical centers in 44 countries, and the primary study objective was to establish the noninferiority of 2 doses of dabigatran compared with warfarin for stroke prevention in patients with AF. The RE-LY investigators (see the online-only Data Supplement) randomized 18 113 patients with AF who had at least 1 additional risk factor for stroke (previous stroke or transient ischemic attack, a left ventricular ejection fraction <40%, New York Heart Association class II or higher heart failure symptoms within 6 months before screening, and an age of at least 75 years or of 65 to 74 years plus diabetes mellitus, hypertension, or coronary artery disease) to receive dabigatran 110 mg twice a day, dabigatran 150 mg twice a day (administered in a blinded fashion), or open-label doseadjusted warfarin (target international normalized ratio, 2.0-3.0) for a median of 2 years. Concomitant use of aspirin (≤100 mg/d) or other antiplatelet agents was permitted.
Follow-up, Events, and Cause-of-Death Definitions
Overall, complete follow-up was achieved in 99.9% of patients, with a total of 20 patients lost to follow-up. 9 Data on mortality (including causes) and major events during follow-up were prospectively collected. 10 Details on deaths were first recorded by local investigators using a standardized form and included a structured narrative description (including location, circumstances of death, and main treatment if initiated). When available, death certificates, hospital discharge summary, and other records (pathology, radiology and laboratory data) were also obtained and transmitted by fax to the Population Health Research Institute, McMaster University (Hamilton, Ontario, Canada) project office. All deaths were independently adjudicated in a blinded manner by 2 members of the events adjudication committee. The events adjudication committee developed standard procedures for determining the cause of death at an initial organizational meeting. Difficult adjudications were regularly discussed during follow-up meetings. The committee was composed of physicians who were experts in different fields such as internal medicine, cardiology, neurology, and critical care medicine.
Deaths were classified as cardiovascular or noncardiovascular (see the online-only Data Supplement). 10 Cardiovascular deaths were further subclassified as cardiac (SCD and progressive heart failure death), vascular (stroke/peripheral embolism, pulmonary embolism, or hemorrhage), and others (which included other cardiovascular causes and those cardiovascular deaths with insufficient information to definitively assign a subclassification). Noncardiovascular deaths included those resulting from malignancy, trauma, or infection. If the cause of death could not be determined from the available evidence, the death was classified as undetermined.
Role of the Funding Source
The study was funded by Boehringer Ingelheim and coordinated by the Population Health Research Institute, which independently managed the database and analyzed the data. An operations committee, with assistance from an international steering committee, was responsible for the design, conduct, and reporting of the study.
Statistical Analysis
Patient characteristics were described as mean±standard deviation, proportions, median and interquartile ranges [IQR] , as appropriate, and compared with t-test or ANOVA (continuous variables) and χ 2 test (categorical variables). Each death was attributed to 1 cause exclusively, and competing-risk analysis was used to calculate rates of death from different causes (SCD, progressive heart failure death, stroke-related death, and hemorrhage-related death). To estimate the cause-specific mortality rates, we used the cumulative incidence function, which is the probability of occurrence by time of a particular type of death in the presence of other risks, and calculated the annual mortality rates. We performed 2 additional sensitivity analyses looking at outcomes (survival) among AF patients with coronary artery disease (n=5029) and symptomatic low left ventricular ejection fraction (≤35% and New York Heart Association class II-IV; n=1092), evaluating the impact of optimal (evidence-based) therapy at baseline. Optimal treatment for coronary artery disease was defined by the use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, β-blockers, statins, and at least 1 additional antiplatelet at baseline; for symptomatic low ejection fraction, optimal treatment was defined by the presence of angiotensin receptor blockers/angiotensin-converting enzyme inhibitors and β-blockers.
We used usual Cox proportional hazards model for overall cardiac mortality. Predictors for other causes of death were based on the proportional subdistribution hazard model; this model is an extension of the Cox proportional hazards model to the competing-risks situation. Multivariate analysis was performed with the backward selection method for the 4 specific causes of death subdistribution hazards to construct a set of independent predictors. This model was also used to compare the incidences of causes of death between dabigatran and warfarin. Major adverse events that occurred after randomization (nonfatal stroke, major bleeding, and myocardial infarction) were considered according to a time-dependent covariate analysis. The variables considered in univariate analysis are summarized in the online-only Data Supplement. Variables with a value of P<0.15 in univariate analysis were then considered in the multivariate model. A 2-sided value of P=0.05 was considered statistically significant. All analyses were performed at the Population Health Research Institute with the use of SAS software, version 9.1 (SAS Institute Inc, Cary, NC).
The authors had full access to the data and designed the statistical analysis, had final responsibility for the decision to submit the manuscript for publication, and vouch for the accuracy and completeness of the data and the analyses.
Results
Patient Characteristics and Factors Associated With Overall Mortality
The mean age of the 18 113 participants was 71.5±9 years; 63.6% were male. Paroxysmal AF was present in 32.8% of the patients, whereas AF was persistent or permanent in the rest. The mean CHADS 2 score was 2.1±1, with congestive heart failure in 32.0%, hypertension in 78.9%, age >75 years in 34.6%, diabetes mellitus in 23.3%, and previous history of stroke/peripheral embolism in 22.4%. A total of 68.2% of patients had previously used vitamin K antagonists. Of the 5793 heart failure patients, 21.7% were in New York Heart Association functional classes III and IV. Patient characteristics according to vital status are summarized in Table 1 . Among patients with coronary artery disease and those with symptomatic low ejection fraction, treatment at baseline and over time is reported in Table 2 .
Significant differences between patients alive at the end of follow-up (n=16 722) and patients who died during followup (n=1371) included age, CHADS 2 score, cardiovascular and lifestyle-related risk factors (alcohol consumption, current tobacco use, diabetes mellitus, obesity), existing heart disease (documented coronary heart disease, heart failure, ventricular dysfunction, ventricular hypertrophy, and intraventricular conduction delay), and other comorbidities (renal insufficiency and cancer history). Independent predictors of overall mortality are reported in 
Different Causes of Death and Effect of Dabigatran Versus Warfarin
A total of 1371 deaths occurred after a median period of 400 days resulting in an annual mortality rate of 3.84% (95% CI, 3.64-4.05). Cumulative incidences of specific categories of deaths are presented in Figure 1 . The majority of deaths were cardiovascular (61.4%), whereas noncardiovascular deaths (principally malignancy) represented 35.8%, and 2.8% of deaths were due to unknown causes (Table 4) . Among cardiovascular deaths, cardiac mortality (SCD and progressive heart failure death) represented 60.4% of deaths with an annual incidence rate of 1.43% (95% CI, 1.31-1.56); the annual incidence rates for SCD and progressive heart failure death were 0.85% (95% CI, 0.76-0.96) and 0.58% (95% CI, 0.50-0.66), respectively. Overall, among the 46 patients with fatal myocardial infarction, 30 (73.2%) died suddenly, 15 (32.6%) died of progressive heart failure, and 1 (2.2%) died of other cardiovascular causes. On the other hand, stroke-related death and fatal hemorrhage represented 11.4% and 4.6% of cardiovascular deaths, respectively, and collectively accounted for only 9.8% of the overall mortality. Although a significant interaction was found for age in terms of the overall mortality (hazard of death, 5.1% in dabigatran group versus 6.8% in warfarin group among people ≤71 years of age, whereas the treatment effect was neutral among those >71 years of age; P=0.02), we found no significant interaction for specific cardiovascular mortality (P=0.09). No significant interaction was found for type of AF.
Causes of death according to warfarin or dabigatran groups are reported in Figure 2 . There was no significant change in the distribution of causes of death in the warfarin group compared with the dabigatran treatment group except for a significant decrease in vascular mortality in the combined dabigatran group (8.8% versus 12.4% in the warfarin group; P=0.029). The annual incidence rates for different causes of death according to antithrombotic agents (dabigatran versus warfarin) are shown in Table 5 . Dabigatran demonstrated a significant effect in reducing vascular death; the annual incidence rate for vascular mortality was significantly lower (0.33%) We found no significant interaction between doses of dabigatran and specific causes of mortality. The outcomes of AF patients with coronary artery disease and symptomatic low ejection fraction, according to whether they were optimally treated or not at baseline, are reported in Table 6 . AF patients with coronary artery disease who were optimally treated demonstrated a trend for a lower incidence of SCD (HR, 0.66; 95% CI, 0.42-1.02; P=0.06). Similarly, AF patients with symptomatic low ejection fraction presented a significantly lower rate of cardiac mortality when optimally treated (HR, 0.55; 95% CI, 0.36-0.84; P=0.006).
Independent Predictors for Specific Cardiovascular Causes of Death
Independent predictors for specific causes of death by multivariate analysis are reported in Tables 7 and 8 .
The strongest independent predictor of cardiac death was heart failure (HR, 3 
Discussion
A better understanding of mechanisms of death in AF patients is required to develop targeted approaches for reducing specific causes of mortality and thus to affect overall mortality. In this regard, we have demonstrated that dabigatran reduces vascular mortality compared with warfarin but has no incremental beneficial effect compared with warfarin on other causes of death, which constitute the vast majority (up to 90%) of deaths in patients with AF receiving appropriate anticoagulant treatment. This implies that future improvements in antithrombotic treatment may add little to further reductions in overall mortality. Anticoagulation therapy (vitamin K antagonists) has been shown to reduce overall mortality in individuals with AF compared with placebo or aspirin when all studies are considered together (relative risk, 0.74; 95% CI, 0.57-0.97), 11 although the differences were most often not significant when considering single studies (except the Boston Area Anticoagulation Trial). Interestingly, in the studies with details on causes of death available, [12] [13] [14] [15] [16] the observed reduction in overall mortality appears to reflect a particular decrease in stroke mortality, which is not outweighed by an increase in hemorrhage-related mortality. In the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) trial, the cause-of-death panel of the 666 total deaths was remarkably similar to that presented here, 17 even though antithrombotic use was incomplete (≈70% in the overall study period) in AFFIRM. Further supporting data are also available from the seminal Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial, [18] [19] [20] which evaluated AF patients with symptomatic low ejection fraction. Cardiac mortality was particularly predominant in this population, and stroke-related mortality represented no more than 2% of the overall mortality. This emphasizes the fact that the absolute burden related to vascular mortality may be even lower in an AF population with high cardiac comorbidity.
Taken together with our results, it would seem that further improvements in antithrombotic therapy are likely to have only modest incremental value in reducing overall mortality. This is not to understate the importance of maintaining good anticoagulation in patients with AF. Indeed, even in the rigorous setting of a randomized, controlled trial such as RE-LY, anticoagulation coverage tended to decline over time, and people who died during follow-up were less likely to be anticoagulated. Furthermore, the relatively low stroke mortality observed in the AF-CHF trial probably reflects the also higher proportion of patients taking an anticoagulant. 19 Keeping in mind the considerable improvement in anticoagulation strategies already achieved in the past decade, further return on investment in this area in terms of mortality reduction could be low. A renewed focus on the evaluation and management of cardiovascular comorbidities seems more appropriate.
Despite the high number of patients enrolled in recent trials testing new antithrombotics in AF patients, little effect on overall mortality has been observed compared to warfarin. 9,21,22 In 21 however, data on cause-specific mortality are not currently available for either study. 21, 22 Examination of the same categories of events across different studies is essential to understand the specific impact of the new antithrombotics compared with warfarin. For example, if the new antithrombotics reduce nonfatal strokes, embolism, and bleeds, it would be logical to explore whether deaths related to these are also reduced; the present study demonstrates that they are reduced.
Interventions to reduce overall mortality in the AF population have produced relatively disappointing results so far. A strategy of using drugs for rhythm control has not been found to be superior to rate control, with even lenient rate control appearing to be an acceptable option. 17, 23, 24 Whether restoration of sinus rhythm with AF ablation will reduce mortality is unknown, and the Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial (CABANA; www.clinicaltrials.gov; NCT00911508), testing the impact of AF catheter ablation on mortality, is ongoing. However, whether AF ablation will reduce mortality when the underlying structural heart disease is unchanged remains to be seen. In the community, AF has been shown to be associated with a large excess risk of death, and the magnitude of this excess risk appears to differ markedly, depending on the timing of AF, with AF developing after heart failure conferring the largest increased risk of death compared with the risk in heart failure patients without AF. 25, 26 Prevention of AF is therefore of critical importance. Treatments such as angiotensin receptor blockers, fish oils, and statins seem to have a favorable effect on limiting atrial remodeling, but no impact on clinically important outcomes has been observed thus far. [27] [28] [29] [30] Overall, cardiovascular risk factor management, optimal treatment of heart failure, and optimal antithrombotic therapy appear to be the cornerstone for improving survival in patients with AF.
Our results also emphasize the prognostic importance of non-fatal stroke and bleeding events. We found that a nonfatal stroke was a significant predictor for stroke-related death, which probably reflects the known association between nonfatal stroke and the subsequent increased risk of future stroke. 31 On the other hand, our results suggesting that an interim bleed predicts death from stroke and that an interim stroke, at a lower level, predicts death from bleeding are novel. Further studies are needed to better understand these findings, particularly the impact of the medical management of such interim events on mortality.
Important strengths of this study include the large sample size, complete follow-up, and adjudication using specific definitions by a blinded committee of expert physicians. However, we acknowledge some limitations. First, this is a post-hoc analysis. Second, the determination of cause-specific mortality, particularly the accuracy of subclassification of deaths, is a difficult task. Although absolute precision in such a subclassification may not be possible, it is likely to be fairly unbiased in a blinded study (especially with central adjudication using standardized definitions), so any errors would be random and would tend to make associations closer to the null. Our findings should form the basis for further investigation or a prospective meta-analysis exploring the impact of antithrombotic therapies on cause-specific mortality. Systemic thromboembolism may be involved in the process of myocardial infarction, progressive heart failure, or even sudden death. However, the probability of such a mechanism significantly influencing our results is likely to be very low. Thromboembolism, resulting from AF or atrial flutter, has been found from angiography and specific heart pathology series to be a potential cause of acute coronary syndrome and sudden death but in an extremely low proportion of cases. [32] [33] [34] [35] Third, a concern inherent to the setting of a randomized, controlled trial is that the population is likely to have fewer comorbidities than may be encountered in the community. Because additional comorbidities may affect outcomes, estimating the extent to which RE-LY patients differ from AF patients in the community is of particular interest. In this regard, a recent analysis demonstrated that patients enrolled in this trial were particularly reflective of the "real-world" AF population. 36 Finally, the aim of our study was to provide a comprehensive assessment of causes of death among a large cohort of patients with AF. For this, the rigorous setting of a randomized, controlled trial was optimal. However, in the absence of a control group (patients without AF), the extent to which the causes of death and their predictors are specific to AF remains to be evaluated.
Conclusions
The majority of deaths are not related to stroke in a contemporary anticoagulated AF population. Dabigatran reduces deaths resulting from vascular causes (but not other causes) compared with warfarin in patients with AF. These results emphasize the need to identify interventions beyond effective anticoagulation to further reduce mortality in atrial fibrillation, especially targeting cardiac mortality. 
CLINICAL PERSPECTIVE
Atrial fibrillation (AF) increases overall mortality. A better understanding of the mechanisms of death in AF patients is required to further refine approaches to reducing the mortality associated with AF. The Randomized Evaluation of LongTerm Anticoagulant Therapy (RE-LY) study (which compared dabigatran etexilate to warfarin), with a mean follow-up of 2 years, provided the opportunity to study causes of deaths and their predictors among a representative set of >18 000 AF patients undergoing anticoagulation. Deaths (1371 deaths), their causes, and major events during follow-up were prospectively collected and blindly adjudicated, and predictors of cause of death were evaluated with competing-risk analysis. Dabigatran significantly reduced vascular-related mortality compared with warfarin but had no effect on other causes of death, which constituted the vast majority (up to 90%) of deaths in this study. This implies that future improvements in antithrombotic treatments may lead to few additional reductions in overall mortality among patients with AF. In contrast, intervening in other mechanisms such as mitigating ventricular remodeling and comprehensive management of cardiovascular risk factors and comorbidities may be more effective in eventually decreasing the 2 most common causes of death in AF patients: sudden cardiac death and death from progressive heart failure. Our results also emphasize the prognostic importance of nonfatal stroke and bleeding events.
